Article -> Article Details

Active pharmaceutical ingredient, or API, is basically the component within any prescribed drug that releases its effect on the human body. Every drug that is developed carries two core components, the API and the excipients, which are the chemically inactive parts of the drug.

The development in medical science has led to the creation of high potency APIs that can produce the desired result of the drug in a much higher capacity. High potency APIs find their usage in treating medical cases that are much beyond the ordinary recourse. Various tests are conducted to determine the API level of a drug and every pharmaceutical company must make their API levels known to the FDA. The expected high potency APIs market share valuation stands at 26.6 billion with a projected CAGR of 8.40% over the forecast period of 2017 to 2023.

The market is primarily driven by the number of investments undertaken by companies in the high potency APIs.  Contractual agencies that provide medical product manufacturing services are growing worldwide and are an extremely budget-friendly option for most pharmaceutical brands, thereby pushing the growth of the market.

Get Sample Copy of Report @ https://www.marketresearchfuture.com/sample_request/6679 

Medical science trends have also added to the cause. Targeted therapy is one of the latest methods of dealing with ailments that make use of high potency APIs. Progresses of health awareness concept amongst developing nations such as India, China, and others have also led to the market growth of high potency APIs.

Competitive Dashboard:

Some of the key players profiled in the report are Teva Pharmaceuticals, SAFC, Carbogen Amics, Bristol-Myers Squibb, Asymchem, Lonza, Bayer AG, Boehringer Ingelheim, and Sanofi.

Market Segmentation

The latest report published by Market Research Future (MRFR) states that the high potency APIs market is segmented based on therapeutic area, type, and product.

• By product, the market divides into biotech and synthetic. It is expected to see that the rising demand for antibody-drug conjugates (ADCs) will lead to the market growth of the biotech segment in the forthcoming years.
• By type, the market includes generic and novel or innovative. The market is spearheaded by the innovative segment. This can be attributed to the availability of huge funds for research & development purposes by the manufacturers.
• By therapeutic area, the market comprises hormonal, oncology, glaucoma, and others. Among all the segments, glaucoma is believed to witness significant growth and demand over the assessment period.

Regional Analysis

The geographical high potency APIs market segmentation covers Europe, Asia-Pacific, Americas, and the Middle East & Africa.

North America holds the top spot in terms of the market growth of high potency APIs and is expected to witness substantial growth over the forecast period. The well-established healthcare sector in the region coupled with the widespread prevalence of chronic diseases is believed to drive the market expansion in the coming years. There is a significant cancer patient pool that lies herein, thus contributing as another key factor responsible for the regional market growth. The region is expected to likely witness an inflow of investments, which will bring-forward both drug innovations and drug developments in the market.

Get Access Full Report @ https://www.marketresearchfuture.com/reports/high-potency-apis-market-6679 

It is also anticipated that the favorable support extended by the government will only help boost the high potency APIs market growth potential. Other factors that are predicted to inversely favor the market expansion of high potency APIs are the changing consumer lifestyle, old age diseases, rising number of biotechnology industries, and so on.

Jan 2nd, 2019, Cambrex Corporation, a leading CDMO specializing in small molecule Active Pharmaceutical Ingredients (APIs), announced the acquisition of Avista Pharma Solutions. The transaction helps boost the position of Cambrex as a leading, fully-integrated small molecule CDMO across the entire drug lifecycle.